DexCom Inc. (DXCM) Upgraded by Desjardins to “Buy”
Several other brokerages also recently commented on DXCM. Jefferies Group reiterated a buy rating and set a $98.00 target price on shares of DexCom in a report on Wednesday, August 3rd. Benchmark Co. dropped their target price on DexCom from $106.00 to $86.00 and set a buy rating on the stock in a report on Wednesday, August 3rd. Deutsche Bank AG raised their target price on DexCom from $90.00 to $98.00 and gave the company a buy rating in a report on Friday, July 15th. Canaccord Genuity reiterated a buy rating and set a $95.00 target price on shares of DexCom in a report on Wednesday, July 13th. Finally, JPMorgan Chase & Co. reiterated a buy rating on shares of DexCom in a report on Monday, June 20th. Four research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $94.96.
Shares of DexCom (NASDAQ:DXCM) traded up 0.19% during midday trading on Friday, reaching $93.24. The company’s stock had a trading volume of 77,402 shares. The firm’s market capitalization is $7.82 billion. DexCom has a 1-year low of $47.92 and a 1-year high of $103.29. The company’s 50-day moving average price is $91.35 and its 200 day moving average price is $74.57.
DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, August 2nd. The medical device company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.12. The firm earned $137.30 million during the quarter, compared to analysts’ expectations of $132.48 million. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. The business’s revenue for the quarter was up 47.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.05) earnings per share. On average, equities research analysts forecast that DexCom will post ($0.57) earnings per share for the current year.
In other DexCom news, SVP Jeffrey Moy sold 4,557 shares of DexCom stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $80.00, for a total transaction of $364,560.00. Following the sale, the senior vice president now owns 76,333 shares of the company’s stock, valued at approximately $6,106,640. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 7,000 shares of DexCom stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $91.79, for a total value of $642,530.00. The disclosure for this sale can be found here. Corporate insiders own 2.80% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Bridger Management LLC acquired a new stake in shares of DexCom during the first quarter valued at $56,651,000. State Street Corp increased its stake in shares of DexCom by 7.2% in the first quarter. State Street Corp now owns 1,055,774 shares of the medical device company’s stock valued at $71,699,000 after buying an additional 71,009 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of DexCom by 17.9% in the first quarter. Renaissance Technologies LLC now owns 817,943 shares of the medical device company’s stock valued at $55,547,000 after buying an additional 124,000 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of DexCom by 6.3% in the first quarter. Geode Capital Management LLC now owns 523,958 shares of the medical device company’s stock valued at $35,581,000 after buying an additional 31,209 shares during the last quarter. Finally, BlackRock Fund Advisors increased its stake in shares of DexCom by 0.6% in the first quarter. BlackRock Fund Advisors now owns 929,897 shares of the medical device company’s stock valued at $63,149,000 after buying an additional 5,443 shares during the last quarter. 99.50% of the stock is currently owned by hedge funds and other institutional investors.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.